肝硬化动物模型的研究进展与中药药效评价思考

中国药物警戒 ›› 2016, Vol. 13 ›› Issue (1): 32-35.

肝硬化动物模型的研究进展与中药药效评价思考

石亮^1,2,孙蓉¹

1.山东省中医药研究院 ,山东济南 250014;
2.山东中医药大学 ,山东济南 250355

收稿日期:2015-10-15 修回日期:2016-02-25 出版日期:2016-01-08 发布日期:2016-02-25
通讯作者: 孙蓉,女,博士,研究员·博导,中药药理与毒理。
作者简介:石亮, 男, 在读硕士, 中药药理学。
基金资助:
国家自然科学基金面上项目(81374059); 山东省自主创新和成果转化项目(2014ZZCX02104)。

Advances in Establishment of Animal Models with Hepatic Cirrhosis and Thinking about Efficacy Evaluation of Traditional Chinese Medicine

SHI Liang^1,2, SUN Rong¹

1.Shandong Academy of Chinese Medicine, Shandong Jinan 250014, China;
2.Shandong University of Traditional Chinese Medicine, Shandong Jinan 250355, China

Received:2015-10-15 Revised:2016-02-25 Online:2016-01-08 Published:2016-02-25

摘要/Abstract

摘要： 目的介绍近年来肝硬化动物模型的研究进展并进行中药药效评价思考。方法对近十几年来国内外相关文献对肝硬化动物模型的报道进行整理、分析和归纳。结果目前主要有两大类建模方案单因素诱导建模及复合因素诱导建模。结论实验中应该根据中药自身的特点来选择合适的动物模型 ,进行候选药物的筛选和药效评价 ,并能够将肝硬化动物模型的研究与临床疾病的研究紧密地结合起来 ,为临床前的中药药理研究和药效评价提供方法学保证。

关键词: 肝硬化, 动物模型, 研究进展

Abstract: Objective To introduce the research development on the advances in establishment of animal models with hepatic cirrhosis and think about efficacy evaluation of traditional Chinese medicine (TCM). Methods The related references in the last decades at home and abroad about cirrhosis model were collated, analyzed and summarized. Results At present, single factor induced modeling and composite factors induced modeling were mainly two categories of the modeling scheme. Conclusion We should choose suitable animal model on the basis of TCM’s characteristic and combine the research of cirrhosis model with clinical disease closely, in order to screen and evaluate candidate drug, and offer methodological ensurance for TCM’s pharmacological preclinical research and efficacy evaluation at the same time.

Key words: hepatic cirrhosis, animal model, research progress

中图分类号:

R965

石亮,孙蓉. 肝硬化动物模型的研究进展与中药药效评价思考[J]. 中国药物警戒, 2016, 13(1): 32-35.

SHI Liang,SUN Rong. Advances in Establishment of Animal Models with Hepatic Cirrhosis and Thinking about Efficacy Evaluation of Traditional Chinese Medicine [J]. Chinese Journal of Pharmacovigilance, 2016, 13(1): 32-35.

参考文献

[1] 张贵阳 ,杨卫平 ,陈皓 .肝硬化动物模型构建的研究进展[J]. 外科理论与实践 , 2008, 13 (3): 266-269.
[2] 陈学新 ,潘华 ,郑月梅 ,等 .肝硬化动物模型的研究进展[J]. 宁夏医科大学学报 , 2009, 5: 080.
[3] 马学惠 .肝纤维化动物模型的造作方法[J]. 中华肝脏病杂志 , 1996, 4 (1): 58-61.
[4] Cameron C R, Karunaratne W A E. Carbon tetrachloride cirrhosis in relation to liver regeneration[J]. J Path Act, 1936, 42 (1): 1-21.
[5] Chae H B, Jang L C, Park S M, et al. An experimental model of hepatic fibrosis induced by alcohol and CCl4: can the lipopolysaccharide
Prevent liver injury induced by alcohol and CCl4 [J]. Taehan Kan Hakhoe Chi, 2002, 8 (2): 173-178.
[6] Jeong W I, Lee C S, Park S J, et al. Kinetics of macrophages, myofibroblasts and mast cells in carbon tetrachloride- induced rat liver cirrhosis [J]. Anticancer Res, 2002, 22 (2A): 869-877.
[7] 王丽春 ,赵连三 .肝纤维化的实验动物模型[J] . 中国实验动物学报 , 2004, 12 (4): 246-250.
[8] 唐映梅 ,杨晋辉 .肝硬化实验动物的模型建立与研究现状 [J] . 实用肝脏病杂志 , 2000, 5( 3) : 191- 193.
[9] 李异玲 ,傅宝玉 ,王炳元 ,等 .实验化学性与酒精性肝纤维化大鼠动物模型的比较[J] . 中国医科大学学报 , 2005, 1 (34): 25-27.
[10] 金峰 ,袁芳 ,薛建设 ,等. 四氯化碳综合法诱导大鼠肝硬化型方法的探讨[J] . 福建医药杂志 , 2003, 25 (5): 127-128.
[11] Kitamura K, Nakamoto Y, Akiyama M, et al. Pathogenic roles of tum or necros is factor receptor p55-m ediated s ignals in dimethylnitrosamine-induced murine liver fibrosis[J]. Lab Invest, 2002, 82 (5): 571- 583.
[12] Waters N J, Waterfield C J, Farrant R D, et al. Metabonomic deconvolution of embedded toxicity: application to thioacetamide hepato-and nephrotoxicity. Chem Res Toxicol, 2005, 18 (4): 639- 654.
[13] Constantinou M A, The ocharis S E, Mikros E. Application of metabonomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in rats[J]. Toxicol Appl Pharmacol, 2007, 218 (1): 11- 19.
[14] Spahr L, Burkhard P R, Grtzsch H, et al. Clinical significance of basal ganglia alterations at brain MRI and 1H MRS in cirrhosis and role in the pathogenesis of hepatic encephalopathy[J].Metab Brain Dis, 2002 , 17( 4) : 399- 413.
[15] 陈拥军 ,邱伟华 ,万亮 ,等. 脾动脉注射IL-2 在大鼠肝癌模型中的定位及其对免疫功能的影响[J]. 外科理论与实践 , 2002, 7 (4): 298- 301.
[16] García-Ayllón M S, Silveyra M X, Candela A, et al.Changes in liver and plasma acetylcholinesterase in rats with cirrhosis induced
by bile duct ligation[J]. Hepatology, 2006, 43 (3): 444- 453.
[17]王宝恩 ,王志富 ,殷蔚英. 实验性免疫性肝纤维化模型的研究 [J]. 中国医学杂志 , 1989, 69: 503- 505
[18] Sakaida I, Hironaka K, Uchida K, et al. Fibrosis accelerates the development of enzyme- altered lesions in the rat liver[J]. He Patology, 1998 , 28( 5) : 1247- 1252
[19] 徐安书. 肝硬化实验动物模型的研究现状[J]. 医学综述 , 2010, 16 (7): 1046-1048.
[20] 周婷 ,杨军 ,王勇. 四氯化碳加乙醇制备实验性肝硬化大鼠模型[J] . 农垦医学 , 2003, 2(25): 152.
[21] Zhang J J, M eng X K, Dong C, et al. Development of a new an in al.model of liver cirrhosis in swine[J] . Eur Surg Res, 2009, 42 (1):
35-39.
[22] 叶春华 ,刘浔阳. 四氯化碳综合法制备大鼠肝硬化模型[J]. 医学临床研究 , 2005, 5 (22): 619-621.
[23] 李栋 ,张乐玲 ,侯怀水 ,等. 四氯化碳诱导兔肝硬化模型的动态研究[J]. 世界华人消化杂志 , 2006, 14 (14) : 1403-1405.
[24] 叶兰 ,熊陶 ,黄能慧 ,等. 高脂饲料和酒精诱导大鼠肝纤维化的实验研究[J] . 贵阳医学院学报 , 2003, 2 (28) : 152-153.
[25] 董琦 ,聂晚频 ,王康. 肝硬化门脉高压症大鼠模型制作方法的探讨[J] . 现代生物医学进展 , 2006, 10 (6): 48-50.
[26] 王丽春, 赵连三. 肝纤维化的实验动物模型[J] . 中国实验动物学报 , 2004, 4 (12): 246-248.
[27] 孙蓉, 杨倩. 肾阳虚证动物模型研制进展与中药药效评价的思考[J] . 药物评价 , 2010, 33 (1) : 22-24
[28] 栾永福, 李晓骄阳, 孙蓉 ,等. 多梗死性脑痴呆模型研制与中药药效评价思考[J]. 中药药理与临床 , 2012, 28 (4): 121-124.